Ensol Biosciences (A140610) Stock Overview
A biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A140610 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Ensol Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,900.00 |
| 52 Week High | ₩38,800.00 |
| 52 Week Low | ₩10,350.00 |
| Beta | 0 |
| 1 Month Change | -7.27% |
| 3 Month Change | 13.19% |
| 1 Year Change | -48.23% |
| 3 Year Change | 6.19% |
| 5 Year Change | -19.19% |
| Change since IPO | 9.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| A140610 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.1% | 1.4% | 8.3% |
| 1Y | -48.2% | 35.2% | 130.0% |
Return vs Industry: A140610 underperformed the KR Biotechs industry which returned 35.2% over the past year.
Return vs Market: A140610 underperformed the KR Market which returned 130% over the past year.
Price Volatility
| A140610 volatility | |
|---|---|
| A140610 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A140610 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A140610's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Hae-Jin Kim | ensolbio.co.kr |
Ensol Biosciences Inc., a biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases. The company’s drug pipeline includes Peniel 2000, which is in Phase III clinical trial for the treatment of degenerative disc disease; Engedi 1000 that is in Phase II clinical trial for the treatment of osteoarthritis; and EAD100, a drug for animal osteoarthritis. It also develops anticancer drugs, such as Charis 1000, which is in Phase I clinical trial for the treatment of triple negative breast cancer; Moriah 1000 that is in pre-clinical stage for the treatment of Alzheimer’s disease; Shiloah 1000, which is in pre-clinical stage for the treatment of type 1 diabetes; Allose 1000 that is in pre-clinical stage for the treatment of atopic dermatitis; EAD200, a drug for animal anti-cancer drug; and EAD300 for the treatment of porcine reproductive and respiratory syndrome.
Ensol Biosciences Inc. Fundamentals Summary
| A140610 fundamental statistics | |
|---|---|
| Market cap | ₩188.03b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
Is A140610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A140610 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A140610 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 23:11 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ensol Biosciences Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.